Aulbio is a biotechnology company specializing in long-acting drug delivery technologies.

We are currently developing once-monthly GLP-1 formulations for obesity treatment, including long-acting semaglutide and tirzepatide injectable products.

Leveraging our proprietary ExTenna™ microsphere platform, we aim to deliver high bioavailability, improved patient convenience, and superior pharmacokinetic performancecompared to existing therapies.

Aulbio is committed to transforming leading peptide therapeutics into next-generation long-acting treatments that enable better outcomes and broader patient access.